Well-preserved liver function enhances the clinical impact of curative-intent subsequent treatment during lenvatinib treatment for unresectable hepatocellular carcinoma
© 2022. Japanese Society of Gastroenterology..
BACKGROUND: The aims of this study were to evaluate the clinical impact of curative-intent subsequent treatment on overall prognosis in lenvatinib-treated hepatocellular carcinoma (HCC) patients.
METHODS: Eighty-three consecutive patients with intrahepatic target nodules who received lenvatinib were reviewed. The clinical impact of curative-intent subsequent treatments was investigated through analysis of overall survival (OS) according to pathological deterioration stratified by mALBI grade.
RESULTS: In patients with mALBI grade 1 and 2a liver function, R0 resection and lenvatinib-transarterial chemoembolization (lenvatinib-TACE) sequential therapy resulted in significantly better OS compared with other, non-curative-intent subsequent therapy and lack of additional treatment (median OS, 37.6 vs 29.0 months and 17.1 vs 8.9 months, respectively; P < 0.001). Multivariate analysis confirmed that use of R0 resection and lenvatinib-TACE sequential therapy were associated with better OS (hazard ratio [HR], 0.021; P < 0.001 and 0.108; P < 0.001) compared with other, non-curative-intent subsequent treatment (HR 0.256; P = 0.010). In contrast, in patients with mALBI grade 2b liver function, multivariate analysis confirmed higher treatment efficacy for non-curative-intent subsequent treatment with respect to OS (HR 0.041; P < 0.001) compared with R0 resection and lenvatinib-TACE sequential therapy (HR 0.057; P = 0.027 and 0.063; P = 0.001).
CONCLUSION: Curative-intent subsequent treatment is more useful for HCC patients with better liver function (mALBI grade 1 and 2a) and intrahepatic target nodules who have received lenvatini b-based treatment.
| Errataetall: |
ErratumIn: Clin J Gastroenterol. 2023 Oct;16(5):791. - PMID 37392310 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Clinical journal of gastroenterology - 16(2023), 1 vom: 07. Feb., Seite 1-12 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kawamura, Yusuke [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
EE083865G2 |
|---|
| Anmerkungen: |
Date Completed 02.02.2023 Date Revised 01.07.2023 published: Print-Electronic ErratumIn: Clin J Gastroenterol. 2023 Oct;16(5):791. - PMID 37392310 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12328-022-01723-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348586302 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348586302 | ||
| 003 | DE-627 | ||
| 005 | 20231226205525.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12328-022-01723-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1161.xml |
| 035 | |a (DE-627)NLM348586302 | ||
| 035 | |a (NLM)36344851 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kawamura, Yusuke |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Well-preserved liver function enhances the clinical impact of curative-intent subsequent treatment during lenvatinib treatment for unresectable hepatocellular carcinoma |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.02.2023 | ||
| 500 | |a Date Revised 01.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Clin J Gastroenterol. 2023 Oct;16(5):791. - PMID 37392310 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. Japanese Society of Gastroenterology. | ||
| 520 | |a BACKGROUND: The aims of this study were to evaluate the clinical impact of curative-intent subsequent treatment on overall prognosis in lenvatinib-treated hepatocellular carcinoma (HCC) patients | ||
| 520 | |a METHODS: Eighty-three consecutive patients with intrahepatic target nodules who received lenvatinib were reviewed. The clinical impact of curative-intent subsequent treatments was investigated through analysis of overall survival (OS) according to pathological deterioration stratified by mALBI grade | ||
| 520 | |a RESULTS: In patients with mALBI grade 1 and 2a liver function, R0 resection and lenvatinib-transarterial chemoembolization (lenvatinib-TACE) sequential therapy resulted in significantly better OS compared with other, non-curative-intent subsequent therapy and lack of additional treatment (median OS, 37.6 vs 29.0 months and 17.1 vs 8.9 months, respectively; P < 0.001). Multivariate analysis confirmed that use of R0 resection and lenvatinib-TACE sequential therapy were associated with better OS (hazard ratio [HR], 0.021; P < 0.001 and 0.108; P < 0.001) compared with other, non-curative-intent subsequent treatment (HR 0.256; P = 0.010). In contrast, in patients with mALBI grade 2b liver function, multivariate analysis confirmed higher treatment efficacy for non-curative-intent subsequent treatment with respect to OS (HR 0.041; P < 0.001) compared with R0 resection and lenvatinib-TACE sequential therapy (HR 0.057; P = 0.027 and 0.063; P = 0.001) | ||
| 520 | |a CONCLUSION: Curative-intent subsequent treatment is more useful for HCC patients with better liver function (mALBI grade 1 and 2a) and intrahepatic target nodules who have received lenvatini b-based treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Hepatocellular carcinoma | |
| 650 | 4 | |a Lenvatinib | |
| 650 | 4 | |a Lenvatinib-transarterial chemoembolization sequential therapy | |
| 650 | 4 | |a Subsequent treatment | |
| 650 | 7 | |a lenvatinib |2 NLM | |
| 650 | 7 | |a EE083865G2 |2 NLM | |
| 700 | 1 | |a Akuta, Norio |e verfasserin |4 aut | |
| 700 | 1 | |a Shindoh, Junichi |e verfasserin |4 aut | |
| 700 | 1 | |a Matsumura, Masaru |e verfasserin |4 aut | |
| 700 | 1 | |a Okubo, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Tominaga, Licht |e verfasserin |4 aut | |
| 700 | 1 | |a Fujiyama, Shunichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Hosaka, Tetsuya |e verfasserin |4 aut | |
| 700 | 1 | |a Saitoh, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Sezaki, Hitomi |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Fumitaka |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Yoshiyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Ikeda, Kenji |e verfasserin |4 aut | |
| 700 | 1 | |a Arase, Yasuji |e verfasserin |4 aut | |
| 700 | 1 | |a Hashimoto, Masaji |e verfasserin |4 aut | |
| 700 | 1 | |a Kozuka, Takuyo |e verfasserin |4 aut | |
| 700 | 1 | |a Kumada, Hiromitsu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical journal of gastroenterology |d 2012 |g 16(2023), 1 vom: 07. Feb., Seite 1-12 |w (DE-627)NLM217862128 |x 1865-7265 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2023 |g number:1 |g day:07 |g month:02 |g pages:1-12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12328-022-01723-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2023 |e 1 |b 07 |c 02 |h 1-12 | ||